Publications by authors named "Philip J Stephens"

100Publications

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.

Cancer Discov 2018 07 17;8(7):822-835. Epub 2018 May 17.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030433PMC
July 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Mol Cancer Ther 2017 11 23;16(11):2598-2608. Epub 2017 Aug 23.

Division of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/lookup/doi/10.1158/1535-7163.MCT
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-17-0386DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670009PMC
November 2017

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.

Eur Urol Focus 2016 Jun 9;2(2):204-209. Epub 2015 Dec 9.

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2015.11.007DOI Listing
June 2016

Genomic Profiling of Small-Bowel Adenocarcinoma.

JAMA Oncol 2017 Nov;3(11):1546-1553

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.1051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710195PMC
November 2017

Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.

J Pediatr Hematol Oncol 2017 05;39(4):e183-e186

*Mary Crowley Cancer Research Centers †Texas Oncology, P.A. ‡Medical City Dallas Hospital ∥ProPath ¶Gradalis Inc. #Strike Bio, Dallas, TX §Foundation Medicine, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000000822DOI Listing
May 2017

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.

J Hematol Oncol 2017 02 28;10(1):64. Epub 2017 Feb 28.

Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA, 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-017-0433-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331657PMC
February 2017

Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.

Am J Dermatopathol 2017 Jan;39(1):1-13

*Professor of Pathology and Dermatology, Albany Medical College, Albany, NY; †Pathology Resident, Unversidade Estadual Paulista, Botucatu, Brazil; ‡Pathology Resident, Albany Medical College, Albany, NY; §Director of Research, Associate Professor, Department of Pathology, Albany, Medical College, Albany, NY; ¶Research and Development, Foundation Medicine, Inc, Cambridge, MA; ‖Chief Medical Officer, Foundation Medicine, Inc, Cambridge, MA; #Chief Scientific Officer, Foundation Medicine, Inc, Cambridge, MA; **Associate Medical Officer, Foundation Medicine, Inc, Cambridge, MA; ††Associate Medical Director, Foundation Medicine, Inc, Cambridge, MA; ‡‡Research Scientist, Foundation Medicine, Inc, Cambridge, MA; §§Chief, Professor of Pathology, Albany, Medical College, Albany, NY; and ¶¶Medical Director, Foundation Medicine, Inc, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000000729DOI Listing
January 2017

Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.

J Natl Compr Canc Netw 2016 11;14(11):1345-1350

From Baylor Health Care System, Dallas, Texas; Foundation Medicine, Inc., Cambridge, Massachusetts; Penn Memory Center, Department of Neurology, Philadelphia, Pennsylvania; Albany Medical College, Albany, New York; and UT Southwestern Medical Center, Dallas, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0145DOI Listing
November 2016

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

J Thorac Oncol 2016 09 22;11(9):1493-502. Epub 2016 Jun 22.

Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.06.004DOI Listing
September 2016

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Cancer Discov 2016 06 21;6(6):601-11. Epub 2016 Apr 21.

Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. Addario Lung Cancer Medical Institute, Cambridge, Massachusetts. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893907PMC
June 2016

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.

Clin Cancer Res 2016 08 1;22(15):3831-40. Epub 2016 Mar 1.

Oncology Division, Department of Internal Medicine, Rhode Island Hospital, and Alpert Medical School at Brown University, Providence, Rhode Island.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-3000DOI Listing
August 2016

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

Oncologist 2016 Jan 15;21(1):33-9. Epub 2015 Dec 15.

Foundation Medicine, Inc., Cambridge, Massachusetts, USA; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California, USA; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA.

View Article

Download full-text PDF

Source
http://www.foundationmedicine.com/wp-content/uploads/2015/12
Web Search
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2015-0241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709208PMC
January 2016

Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib.

J Natl Cancer Inst 2016 Jan 12;108(1). Epub 2015 Nov 12.

Rady Childrens Hospital, San Diego, CA (VW, JC, DM, HA); Foundation Medicine, Inc., Cambridge, MA (DP, TB, RY, JSR, VAM, PJS, SMA); Albany Medical College, Albany, NY (JSR).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/108/1/djv307.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djv307
Publisher Site
http://dx.doi.org/10.1093/jnci/djv307DOI Listing
January 2016

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets.

J Clin Pathol 2016 May 23;69(5):403-8. Epub 2015 Oct 23.

Department of Pathology, Albany Medical College, Albany, New York, USA Foundation Medicine, Inc., Cambridge, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2015-203394DOI Listing
May 2016

Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.

Oncologist 2015 Oct 2;20(10):1132-9. Epub 2015 Sep 2.

Foundation Medicine, Inc., Cambridge, Massachusetts, USA; Division of Hematology-Oncology, University of California Irvine, Orange, California, USA; The Ohio State University-James Cancer Hospital, Columbus, Ohio, USA; National Translational Research Group, New York, New York, USA; Albany Medical College, Albany, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591943PMC
October 2015

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

Lung Cancer 2015 Sep 29;89(3):357-9. Epub 2015 Jun 29.

Division of Hematology-Oncology, Department of Medicine, Chao Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.06.021DOI Listing
September 2015

Genomic Profiling of Cancers of Unknown Primary Site--Reply.

JAMA Oncol 2015 Jul;1(4):542-3

Foundation Medicine, Inc, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.0945DOI Listing
July 2015

Multiple gene aberrations and breast cancer: lessons from super-responders.

BMC Cancer 2015 May 29;15:442. Epub 2015 May 29.

Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California at San Diego Moores Cancer Center, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1439-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446801PMC
May 2015

Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.

Arch Pathol Lab Med 2015 May;139(5):642-9

From the Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York (Drs Ross and Boguniewicz and Ms Sheehan); Research and Development, Foundation Medicine, Inc, Cambridge, Massachusetts (Drs Ross, Wang, Otto, Yelensky, Lipson, Ali, Morosini, Chliemlecki, Elvin, Miller, and Stephens); and the Department of Pathology, University of Indiana School of Medicine, Indianapolis (Dr Badve).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2014-0200-OADOI Listing
May 2015

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.

BMC Cancer 2015 Feb 18;15:61. Epub 2015 Feb 18.

Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1029-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340232PMC
February 2015

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Oncologist 2015 May 16;20(5):499-507. Epub 2015 Apr 16.

Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University of Chicago, Chicago, Illinois, USA; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425384PMC
May 2015